Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 1, Human | 26 | 2016 | 54 | 3.490 |
Why?
|
| Keratitis, Herpetic | 15 | 2016 | 18 | 2.610 |
Why?
|
| Apolipoproteins E | 8 | 2016 | 129 | 2.590 |
Why?
|
| Virus Latency | 16 | 2012 | 42 | 1.770 |
Why?
|
| Peptide Fragments | 5 | 2016 | 298 | 1.490 |
Why?
|
| Antiviral Agents | 8 | 2016 | 148 | 1.210 |
Why?
|
| Diabetic Retinopathy | 2 | 2016 | 65 | 1.070 |
Why?
|
| Virus Activation | 11 | 2012 | 35 | 0.860 |
Why?
|
| Retina | 2 | 2016 | 255 | 0.850 |
Why?
|
| DNA, Viral | 9 | 2012 | 295 | 0.810 |
Why?
|
| Herpes Simplex | 4 | 2012 | 16 | 0.710 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2016 | 87 | 0.660 |
Why?
|
| Disease Models, Animal | 14 | 2016 | 1300 | 0.600 |
Why?
|
| Rabbits | 17 | 2013 | 278 | 0.590 |
Why?
|
| Retinal Neovascularization | 1 | 2016 | 9 | 0.590 |
Why?
|
| Stephania | 1 | 2016 | 1 | 0.580 |
Why?
|
| Leucine | 1 | 2016 | 28 | 0.570 |
Why?
|
| Fructose | 1 | 2016 | 23 | 0.570 |
Why?
|
| Receptors, LDL | 1 | 2016 | 30 | 0.570 |
Why?
|
| Eye | 3 | 2016 | 68 | 0.570 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 56 | 0.560 |
Why?
|
| Animals | 33 | 2019 | 14307 | 0.550 |
Why?
|
| Analgesics | 1 | 2016 | 56 | 0.550 |
Why?
|
| Trigeminal Ganglion | 8 | 2011 | 13 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 184 | 0.510 |
Why?
|
| Mice, Inbred C57BL | 7 | 2018 | 1530 | 0.510 |
Why?
|
| Mice | 15 | 2018 | 5668 | 0.490 |
Why?
|
| Endothelial Cells | 2 | 2018 | 296 | 0.490 |
Why?
|
| Plant Extracts | 1 | 2016 | 250 | 0.460 |
Why?
|
| Pain | 1 | 2016 | 249 | 0.460 |
Why?
|
| Virus Shedding | 1 | 2012 | 9 | 0.450 |
Why?
|
| MicroRNAs | 7 | 2019 | 386 | 0.450 |
Why?
|
| Saliva | 2 | 2012 | 97 | 0.430 |
Why?
|
| Extracellular Matrix | 1 | 2012 | 111 | 0.420 |
Why?
|
| Epithelium, Corneal | 2 | 2009 | 11 | 0.410 |
Why?
|
| Glucose | 1 | 2012 | 217 | 0.400 |
Why?
|
| Corneal Stroma | 2 | 2008 | 6 | 0.390 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 122 | 0.370 |
Why?
|
| Peptides | 1 | 2012 | 308 | 0.370 |
Why?
|
| Thymidine Kinase | 1 | 2009 | 7 | 0.350 |
Why?
|
| Cornea | 7 | 2013 | 55 | 0.340 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1149 | 0.290 |
Why?
|
| Epinephrine | 3 | 2003 | 35 | 0.270 |
Why?
|
| Acyclovir | 3 | 2010 | 5 | 0.250 |
Why?
|
| Butyrates | 3 | 2011 | 31 | 0.250 |
Why?
|
| Blotting, Western | 2 | 2016 | 834 | 0.240 |
Why?
|
| Tears | 4 | 2012 | 11 | 0.240 |
Why?
|
| Simplexvirus | 1 | 2003 | 10 | 0.240 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 756 | 0.230 |
Why?
|
| Exons | 1 | 2003 | 80 | 0.230 |
Why?
|
| Sequence Deletion | 1 | 2003 | 87 | 0.230 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2011 | 605 | 0.220 |
Why?
|
| Mice, Inbred BALB C | 5 | 2019 | 649 | 0.220 |
Why?
|
| Calcium-Binding Proteins | 2 | 2019 | 72 | 0.210 |
Why?
|
| Trifluridine | 3 | 2011 | 3 | 0.200 |
Why?
|
| Neovascularization, Physiologic | 2 | 2019 | 70 | 0.200 |
Why?
|
| Fluorescein Angiography | 2 | 2018 | 9 | 0.190 |
Why?
|
| Ophthalmic Solutions | 2 | 2011 | 18 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 157 | 0.180 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2019 | 16 | 0.170 |
Why?
|
| Viral Load | 2 | 2012 | 300 | 0.170 |
Why?
|
| Genetic Loci | 1 | 2019 | 70 | 0.170 |
Why?
|
| Choroid | 1 | 2018 | 10 | 0.160 |
Why?
|
| Hot Temperature | 2 | 2016 | 120 | 0.160 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 2011 | 108 | 0.150 |
Why?
|
| Valine | 2 | 2010 | 31 | 0.150 |
Why?
|
| Leukostasis | 1 | 2016 | 4 | 0.150 |
Why?
|
| Blood-Retinal Barrier | 1 | 2016 | 8 | 0.150 |
Why?
|
| Fundus Oculi | 1 | 2016 | 5 | 0.150 |
Why?
|
| Retinal Vessels | 1 | 2016 | 24 | 0.150 |
Why?
|
| Capillary Permeability | 1 | 2016 | 30 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2016 | 39 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 968 | 0.140 |
Why?
|
| Female | 11 | 2019 | 19873 | 0.140 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 47 | 0.140 |
Why?
|
| Formaldehyde | 1 | 2016 | 33 | 0.140 |
Why?
|
| Acetic Acid | 1 | 2016 | 16 | 0.140 |
Why?
|
| Naloxone | 1 | 2016 | 50 | 0.140 |
Why?
|
| Narcotic Antagonists | 1 | 2016 | 50 | 0.140 |
Why?
|
| Genes, Viral | 2 | 2008 | 62 | 0.140 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 68 | 0.140 |
Why?
|
| Receptors, Opioid | 1 | 2016 | 50 | 0.140 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2018 | 283 | 0.140 |
Why?
|
| Phytotherapy | 1 | 2016 | 62 | 0.140 |
Why?
|
| Plant Leaves | 1 | 2016 | 110 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 984 | 0.130 |
Why?
|
| Glutamic Acid | 1 | 2016 | 115 | 0.130 |
Why?
|
| Male | 5 | 2016 | 18870 | 0.130 |
Why?
|
| Blood Glucose | 1 | 2016 | 333 | 0.130 |
Why?
|
| Betaine | 1 | 2013 | 7 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 298 | 0.120 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2013 | 34 | 0.120 |
Why?
|
| Eye Infections, Viral | 1 | 2012 | 4 | 0.110 |
Why?
|
| Dexamethasone | 2 | 2011 | 43 | 0.110 |
Why?
|
| Cell Movement | 2 | 2019 | 545 | 0.110 |
Why?
|
| Down-Regulation | 3 | 2010 | 420 | 0.110 |
Why?
|
| Humans | 13 | 2019 | 34853 | 0.100 |
Why?
|
| Ganciclovir | 1 | 2011 | 4 | 0.100 |
Why?
|
| Conjunctivitis, Viral | 1 | 2011 | 1 | 0.100 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 4 | 0.100 |
Why?
|
| Povidone-Iodine | 1 | 2011 | 2 | 0.100 |
Why?
|
| Disease Reservoirs | 1 | 2011 | 20 | 0.100 |
Why?
|
| Umbilical Veins | 1 | 2011 | 16 | 0.100 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2011 | 13 | 0.100 |
Why?
|
| Dipeptides | 1 | 2011 | 29 | 0.100 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 45 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 69 | 0.090 |
Why?
|
| Mice, Knockout | 2 | 2018 | 897 | 0.090 |
Why?
|
| Recurrence | 4 | 2012 | 125 | 0.090 |
Why?
|
| Genes, MHC Class II | 1 | 2009 | 20 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 229 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2010 | 287 | 0.090 |
Why?
|
| Acute Disease | 1 | 2009 | 141 | 0.080 |
Why?
|
| Corneal Opacity | 1 | 2008 | 1 | 0.080 |
Why?
|
| Corneal Neovascularization | 1 | 2008 | 6 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2011 | 1349 | 0.080 |
Why?
|
| Virulence | 2 | 2006 | 221 | 0.080 |
Why?
|
| Eye Proteins | 1 | 2008 | 46 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 528 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 41 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 197 | 0.080 |
Why?
|
| Gene Expression | 2 | 2008 | 639 | 0.080 |
Why?
|
| Mutation | 2 | 2009 | 1023 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 608 | 0.070 |
Why?
|
| Genome, Viral | 1 | 2006 | 103 | 0.070 |
Why?
|
| Genotype | 1 | 2008 | 641 | 0.070 |
Why?
|
| Survival Rate | 1 | 2006 | 310 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 396 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 550 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 430 | 0.070 |
Why?
|
| Viral Proteins | 2 | 2003 | 172 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 600 | 0.060 |
Why?
|
| Cytokines | 1 | 2008 | 569 | 0.060 |
Why?
|
| Virus Replication | 1 | 2006 | 261 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1152 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2011 | 490 | 0.060 |
Why?
|
| Chimera | 1 | 2003 | 15 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2003 | 9 | 0.060 |
Why?
|
| Prodrugs | 1 | 2003 | 22 | 0.060 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2003 | 48 | 0.060 |
Why?
|
| Herpesvirus 5, Bovine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 484 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2002 | 61 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2002 | 154 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1442 | 0.050 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2019 | 26 | 0.040 |
Why?
|
| Species Specificity | 2 | 2012 | 233 | 0.040 |
Why?
|
| Histones | 2 | 2011 | 177 | 0.040 |
Why?
|
| Plasmids | 1 | 2018 | 233 | 0.040 |
Why?
|
| Neurons | 1 | 2003 | 1130 | 0.030 |
Why?
|
| Models, Biological | 1 | 2019 | 642 | 0.030 |
Why?
|
| Proteins | 1 | 2018 | 352 | 0.030 |
Why?
|
| Iontophoresis | 2 | 2003 | 13 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2011 | 5 | 0.030 |
Why?
|
| Tobramycin | 1 | 2011 | 3 | 0.030 |
Why?
|
| Conjunctiva | 1 | 2011 | 6 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 27 | 0.030 |
Why?
|
| Macaca | 1 | 2011 | 38 | 0.030 |
Why?
|
| Nucleosomes | 1 | 2011 | 27 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2011 | 59 | 0.020 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2010 | 2 | 0.020 |
Why?
|
| Vero Cells | 1 | 2011 | 90 | 0.020 |
Why?
|
| Cytosine | 1 | 2011 | 33 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 171 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 96 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 217 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 74 | 0.020 |
Why?
|
| Neuroglia | 1 | 2010 | 117 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 74 | 0.020 |
Why?
|
| Chemokine CCL8 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 137 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2007 | 71 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 34 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 429 | 0.020 |
Why?
|
| Sodium | 1 | 2007 | 101 | 0.020 |
Why?
|
| Macular Degeneration | 1 | 2006 | 27 | 0.020 |
Why?
|
| Chromatin | 1 | 2007 | 164 | 0.020 |
Why?
|
| Androgens | 1 | 2006 | 87 | 0.020 |
Why?
|
| Alleles | 1 | 2006 | 284 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 1007 | 0.020 |
Why?
|
| Estrogens | 1 | 2006 | 190 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 859 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2007 | 628 | 0.020 |
Why?
|
| Culture Techniques | 1 | 2003 | 23 | 0.010 |
Why?
|
| Aqueous Humor | 1 | 2003 | 18 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 35 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 84 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 34 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2003 | 84 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 52 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 109 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 74 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2003 | 72 | 0.010 |
Why?
|
| Encephalitis, Viral | 1 | 2002 | 6 | 0.010 |
Why?
|
| Meningoencephalitis | 1 | 2002 | 13 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 18 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 200 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 296 | 0.010 |
Why?
|
| Olfactory Bulb | 1 | 2002 | 48 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 472 | 0.010 |
Why?
|
| Phenotype | 1 | 2003 | 650 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 455 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 932 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 881 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 1124 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 1289 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1490 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 3414 | 0.010 |
Why?
|
| Aged | 1 | 2008 | 6448 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 3261 | 0.010 |
Why?
|
| Middle Aged | 1 | 2008 | 9642 | 0.010 |
Why?
|